All told, financing fell 41% to almost $33 billion last year from its 2021 peak of nearly $56 billion, according to a new report from Galen Growth and FINN Partners, but behind that top-line figure is a larger body of backers with less extravagance and higher expectations for proof points and a return on their investment.
The prevailing trend – that looks set to continue into 2023 and beyond – is the direction of a smaller pot of money towards digital health ventures that can offer “clinical strength”; in other words, those that can demonstrate an evidence-based approach drawing on clinical trials, regulatory fil
